Drug intelligence / Profile preview

umbilical cord mesenchymal stem cells + heparin

Development stage: Unknown
Modality: Small Molecules, Stem Cell Therapies → Cell Therapies
Administration: Intravenous (for Both Components), Local Injection (for Wound/tissue Applications)

Overview

This is a combination therapy consisting of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) and heparin. UC-MSCs are multipotent stromal cells capable of differentiating into various cell types, including osteocytes and neurons, and are known for their immunomodulatory, anti-inflammatory, and regenerative properties. Heparin is an anticoagulant that also modulates cellular differentiation pathways. In this combination, heparin has been shown to interact with the WWTR1 protein in UC-MSCs, promoting osteogenic differentiation by upregulating genes such as RUNX2 and COL1A1 while downregulating pluripotency markers like OCT4 and Nanog[2]. The combination may be used experimentally to enhance tissue repair or regeneration in conditions such as diabetic foot ulcers or other degenerative diseases[5][2][3].

Other names: umbilical cord mesenchymal stem cells + heparin

Targets

TAZ (Transcriptional coactivator with PDZ-binding motif)F10 (Factor Xa)ATIII (Antithrombin III)F2 (Thrombin)

Beyond the preview

Go deeper on umbilical cord mesenchymal stem cells + heparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on umbilical cord mesenchymal stem cells + heparin.

Explore the full profile